PURPOSE: To determine the sensitivity of fluorodeoxyglucose (FDG) positron emission
tomography (PET) in patients with T1 (≤ 3 cm) lung cancers. MATERIALS AND METHODS …

Over the past several years, positron emission tomography (PET) has become a clinically
useful, noninvasive study which complements conventional imaging (chest radiographs …

Over the past years, positron emission tomography (PET) with fluoro-2-deoxy-d-glucose
(FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been …

Aim In this study, we aimed to compare the diagnostic accuracy of 18 F− fluorodeoxyglucose
(18 F-FDG) and Gallium-68 labeled fibroblast activator protein inhibitor (68 Ga-FAPI)-04 …

Lung cancer has been the leading cause of cancer-related mortality in China in recent
decades. Positron emission tomography-computer tomography (PET/CT) has been …

Positron emission tomography (PET) with 18F‐fluoro‐2‐deoxyglucose (FDG) has recently
emerged as a practical and useful imaging modality in patients with lung cancer. Malignant …

Aim Bronchioloalveolar (BAC) cancer is a source of false-negative 18 F-fluorodeoxyglucose
(FDG) PET/computed tomography (CT) results. A few studies reported better diagnostic …

PURPOSE: To prospectively study the impact of 18F fluorodeoxyglucose (FDG) positron
emission tomography (PET) on clinical management of patients with non–small-cell lung …

Since its introduction in 1974, positron emission tomography (PET) has gained widespread
use, especially in diagnosis and staging of lung cancer. In this respect, 18F …

In the past 5 yrs, positron emission tomography (PET) with 18F-fluoro-2-deoxy-d-glucose
(FDG) has become an important imaging modality in lung cancer patients. At this time, the …